NASDAQ: NKGN
Nkgen Biotech Inc Earnings Dates, Reports, Calls

Nkgen Biotech earnings were -$88.3M for the trailing 12 months ending Jun 30, 2024, with N/A growth year over year. The latest NKGN earnings report on Jun 30, 2024 announced Q2 2024 earnings of -$16.1M, up 198.9% from last quarter. For the last reported fiscal year 2023 ending Dec 31, 2023, NKGN reported annual earnings of -$83.0M, with 210.1% growth.

NKGN earnings history

Current Revenue
$0.0
Current Earnings
-$88.3M
Current Profit Margin
0%

NKGN Return on Equity

Insufficient data to display

NKGN Return on Assets

Current Company
-479.4%
Current Industry
3.5%
NKGN is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when NKGN announces earnings.

NKGN Return on Capital Employed

Current Company
240.16%
Current Industry
21.3%

NKGN vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
NKGN-$84.45M-$88.25MN/A-$5.08
SYBX-$41.63M-$44.20MN/A-$2.09
DWTX-$5.73M-$5.73MN/A-$6.30
GOVX-$24.20M-$24.32MN/A-$9.31
MTVA-$27.71M-$27.73MN/A-$4.74

Nkgen Biotech Earnings Reports & History FAQ

What were Nkgen Biotech's earnings last quarter?

Nkgen Biotech (NASDAQ: NKGN) reported Q2 2024 earnings per share (EPS) of -$0.67, up 13.56% year over year. Total NKGN earnings for the quarter were -$16.09 million. In the same quarter last year, Nkgen Biotech's earnings per share (EPS) was -$0.59.

If you're new to stock investing, here's how to buy Nkgen Biotech stock.

Is Nkgen Biotech profitable or losing money?

As of the last Nkgen Biotech earnings report, Nkgen Biotech is currently losing money. Nkgen Biotech's net profit (also called net income) for the twelve months ending Jun 30, 2024 was -$88.25 million, a 196.03% increase year over year.

What was NKGN's earnings growth in the past year?

As of Nkgen Biotech's earnings date in Q1 2025, Nkgen Biotech's earnings has grown year over year. NKGN earnings in the past year totalled -$88.25 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.